| Literature DB >> 19043778 |
Andrew D Norden1, Jan Drappatz, Alona Muzikansky, Karly David, Mary Gerard, M Brenna McNamara, Phuong Phan, Ainsley Ross, Santosh Kesari, Patrick Y Wen.
Abstract
Recent clinical trial results suggest that anti-angiogenic therapy may be effective against recurrent malignant glioma. Though these treatments prolong progression-free survival, the extent to which they prolong overall survival is unknown. We pooled data from 34 patients treated at a single institution on phase II clinical trials of bevacizumab and cediranib, and we compared these data to 18 patients treated on clinical trials of cytotoxic chemotherapies. In univariate and multivariate analyses, treatment group was a significant predictor of progression-free but not overall survival. Median progression-free survival was 8 vs. 22 weeks in patients treated with cytotoxic as compared to anti-angiogenic therapy (P = 0.01). Median overall survival was nearly identical in the two groups (39 vs. 37 weeks). The results of this exploratory analysis suggest that anti-angiogenic therapy may fail to prolong overall survival in patients with recurrent malignant glioma. If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19043778 DOI： 10.1007/s11060-008-9745-8
Source DB: PubMed Journal: J Neurooncol ISSN： 0167-594X Impact factor: 4.130